Skip to main content

IPAB Allowed Appeal and Granted Patent Related to The Pharmaceutical Composition of Coenzyme Q10

The IPAB allowed an appeal and granted a patent related to the pharmaceutical composition of coenzyme Q10 to the University of Miami.

The application claims were directed to pharmaceutical composition comprising coenzyme Q10 and the method of using coenzyme Q10 for treatment of cancer. A composition of coenzyme Q10 comprising a lipid has also been exemplified in the specification. During prosecution of the application, the claims were revised and the method of treatment claims were deleted in response to the objection of the Controller, the composition claims were revised and limited to be directed to liposomal composition for the treatment of cancer comprising 0.01 to 30% w/w co-enzyme Q10 and a liposome for topical and intravenous administration. The applicant also relied upon post published data confirming and further supporting results provided in specification. The application was refused on various grounds including that the use of liposomes is known, and that post filing data cannot be considered. The application was also considered to be a method of treatment.

 The IPAB allowed the appeal, granted the patent and held that:-

  • Controller failed to consider the facts and evidence produced by the appellant, merely vague order has been passed.
  • Controller is wrong in rejecting the application as the same is a breakthrough invention for treatment of cancer, an embodiment of which is being studied at the clinical stage for treatment of cancer.
  • The claims are novel and also inventive in view of the cited documents and completely supported by the specification as originally filed.
  • Filing of additional documents, data and evidence in support of the invention, to overcome the objection raised and to attack a specific objection is something which is allowed under the Patent Law of not only India but also other foreign jurisdictions.
Most Recent

News & Insights

VIEW ALL
News & Updates
Jan 02, 2026

First published by Lexology. Authors: Pravin Anand, Saif Khan, Shobhit Agarwal and Prajjwal Kushwaha A. Background B. Legal Issues Addressed C. Directions

LANDMARK RULING ON DOMAIN NAME FRAUD AND SYSTEMIC REFORMS IN DIGITAL COMMERCE
Thought Leadership
Jan 01, 2026

First published on Enterprise IT World. Authored by Subroto Kumar Panda As we stand on the final day of 2025, reflecting on a year of dizzying

The Great Dissolve: Re-Engineering Enterprise Workflows for the 2026 AI Paradigm
Thought Leadership
Dec 19, 2025

First published on Express Computer. Authored by Subroto Kumar Panda The notification of the Digital Personal Data Protection (DPDP) Rules, 2025, marks

The DPDP: An 18-month compliance imperative for the C-suite
News & Updates, Thought Leadership
Dec 16, 2025

‘First published on India Business Law Journal’ By: Pravin Anand and Dr. Ajai Garg Artificial Intelligence (AI) is fuelling one of the most significant

Law Can Keep Us Safe From Superintelligence